Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12103354 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL2600693 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL12621036 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL13534760 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL13537546 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL6840473 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| Dimethylamine SCHEMBL29014940 | 0.94 | SIGMAR1 (0.48) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL29014928 | 0.85 | AGXT (0.40) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL19320786 | 0.84 | LTA4H (0.50) | SIGMAR1SLC6A2MAOASLC6A3MEN1 | |
| SCHEMBL8613025 | 0.82 | HTR6 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071270-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180021436-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | BRISTOL MYERS SQUIBB CO (US) | 2018-01-25 | — | — | US | disclosed |
| US-20150320731-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150202191-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150080399-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT | BRISTOL MYERS SQUIBB CO (US) | 2015-03-19 | — | — | US | disclosed |
| US-20130266648-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2013-10-10 | — | — | US | disclosed |
| US-8513428-B2 | Process for preparing atazanavir bisulfate and novel forms | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130203759-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT | BRISTOL-MYERS SQUIBB COMPANY | 2013-08-08 | — | — | US | disclosed |
| US-20130116457-A1 | CLEAN, HIGH-YIELD PREPARATION OF S,S AND R,S AMINO ACID ISOSTERES | AEROJET FINE CHEMICALS LLC (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130096317-A1 | REDUCTION OF ALDEHYDES AND KETONES TO ALCOHOLS | GEORGIA TECH RESEARCH CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-7829720-B2 | Process for preparing atazanavir bisulfate and novel forms | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100183716-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | Bristo-Meyers Squibb Company | 2010-07-22 | — | — | US | disclosed |
| US-20100183715-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | Bristo-Meyers Squibb Company | 2010-07-22 | — | — | US | disclosed |
| US-20100178339-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-15 | — | — | US | disclosed |
| US-20100178340-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-15 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090203630-A1 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090012303-A1 | CLEAN, HIGH-YIELD PREPARATION OF S,S AND R,S AMINO ACID ISOSTERES | AEROJET FINE CHEMICALS LLC (US) | 2009-01-08 | — | — | US | disclosed |
| US-7309803-B2 | Clean, High-yield preparation of S,S and R,S amino acid isosteres | AEROJET FINE CHEMICALS LLC (US) | 2007-12-18 | — | — | US | disclosed |
| US-7189864-B2 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183715-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | SIGMAR1 2769/4885TAAR1 4223/4885SLC6A2 2812/4885 |
| US-20130203759-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT | ACIN1, SAMHD1, ARSA | SIGMAR1 3042/4885TAAR1 4344/4885SLC6A2 1049/4885 |
| US-20180071270-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | SIGMAR1 2769/4885TAAR1 4223/4885SLC6A2 2812/4885 |
| US-20100183716-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | SIGMAR1 2769/4885TAAR1 4223/4885SLC6A2 2812/4885 |
| US-20090012303-A1 | CLEAN, HIGH-YIELD PREPARATION OF S,S AND R,S AMINO ACID ISOSTERES | SRMS, HCK, BHMT2 | SIGMAR1 1912/4885TAAR1 2357/4885SLC6A2 3986/4885 |
| US-20130266648-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | SIGMAR1 2769/4885TAAR1 4223/4885SLC6A2 2812/4885 |
| US-20100178339-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | SIGMAR1 2769/4885TAAR1 4223/4885SLC6A2 2812/4885 |
| US-20150320731-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | SIGMAR1 2769/4885TAAR1 4223/4885SLC6A2 2812/4885 |
| US-20090203630-A1 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | GTF3C3, PRSS3, GTF3C4 | SIGMAR1 2092/4885TAAR1 3122/4885SLC6A2 3123/4885 |
| US-20130096317-A1 | REDUCTION OF ALDEHYDES AND KETONES TO ALCOHOLS | POF1B, PHF2, ADH1C | SIGMAR1 3352/4885TAAR1 334/4885SLC6A2 4080/4885 |
| US-20100178340-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | SIGMAR1 2769/4885TAAR1 4223/4885SLC6A2 2812/4885 |
| US-20130116457-A1 | CLEAN, HIGH-YIELD PREPARATION OF S,S AND R,S AMINO ACID ISOSTERES | SRMS, HCK, BHMT2 | SIGMAR1 1912/4885TAAR1 2357/4885SLC6A2 3986/4885 |
| US-20150080399-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT | ACIN1, SAMHD1, ARSA | SIGMAR1 3042/4885TAAR1 4344/4885SLC6A2 1049/4885 |
| US-20180021436-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | ACIN1, SAMHD1, ARSA | SIGMAR1 3042/4885TAAR1 4344/4885SLC6A2 1049/4885 |
| US-20150202191-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | SIGMAR1 2769/4885TAAR1 4223/4885SLC6A2 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.